In the kidney, FGF23 acts on FGFR/klotho complex to suppress the expression of hypoxia-inducible factor-1α (HIF-1α), thereby reducing renal erythropoietin (EPO) secretion in patients with CKD [33, 34]. The gene discussed is EPO; the disease is chronic kidney disease.